Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in the United States.
Flawless balance sheet with weak fundamentals.
Share Price & News
How has Aptose Biosciences's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: LTIA's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: LTIA exceeded the German Biotechs industry which returned -5.1% over the past year.
Return vs Market: LTIA exceeded the German Market which returned -17.7% over the past year.
Price Volatility Vs. Market
How volatile is Aptose Biosciences's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Aptose Biosciences undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate LTIA's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate LTIA's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: LTIA is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: LTIA is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate LTIA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: LTIA is overvalued based on its PB Ratio (4.8x) compared to the DE Biotechs industry average (3.6x).
How is Aptose Biosciences forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: LTIA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: LTIA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: LTIA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if LTIA's revenue is forecast to grow faster than the German market.
High Growth Revenue: Insufficient data to determine if LTIA's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if LTIA's Return on Equity is forecast to be high in 3 years time
How has Aptose Biosciences performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: LTIA is currently unprofitable.
Growing Profit Margin: LTIA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: LTIA is unprofitable, and losses have increased over the past 5 years at a rate of -22.2% per year.
Accelerating Growth: Unable to compare LTIA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: LTIA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (8.7%).
Return on Equity
High ROE: LTIA has a negative Return on Equity (-27.98%), as it is currently unprofitable.
How is Aptose Biosciences's financial position?
Financial Position Analysis
Short Term Liabilities: LTIA's short term assets ($98.8M) exceed its short term liabilities ($5.5M).
Long Term Liabilities: LTIA's short term assets ($98.8M) exceed its long term liabilities ($1.0M).
Debt to Equity History and Analysis
Debt Level: LTIA is debt free.
Reducing Debt: LTIA has no debt compared to 5 years ago when its debt to equity ratio was 1.4%.
Inventory Level: LTIA has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if LTIA's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: LTIA has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: LTIA has sufficient cash runway for 2.1 years if free cash flow continues to reduce at historical rates of -20.4% each year.
What is Aptose Biosciences's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate LTIA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate LTIA's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if LTIA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if LTIA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of LTIA's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
William Rice (60yo)
Dr. William G. Rice, Ph.D., has been the Chief Executive Officer and President of Aptose Biosciences Inc. since October 28, 2013. Dr. Rice served as the President and Chief Executive Officer of Cylene Phar ...
CEO Compensation Analysis
Compensation vs Market: William's total compensation ($USD2.50M) is above average for companies of similar size in the German market ($USD1.03M).
Compensation vs Earnings: William's compensation has increased whilst the company is unprofitable.
|Executive VP||6.25yrs||US$1.79m||0.18% $725.0k|
|Senior VP of Medical Affairs||no data||no data||no data|
|Senior VP & Chief Business Officer||0.75yr||no data||0.052% $215.6k|
|Senior VP & Chief Medical Officer||0.17yr||no data||no data|
Experienced Management: LTIA's management team is seasoned and experienced (6.3 years average tenure).
|Senior VP of Medical Affairs||no data||no data||no data|
|Independent Director||12.5yrs||US$173.71k||0.0085% $35.0k|
|Lead Independent Director||no data||US$221.71k||0.021% $87.6k|
|Independent Director||5.25yrs||US$169.71k||0.18% $727.6k|
|Independent Director||8.92yrs||US$173.71k||0.066% $269.5k|
|Independent Director||1.92yrs||US$99.34k||no data|
|Chairman of Scientific Advisory Board||6.42yrs||no data||no data|
|Member of Scientific Advisory Board||5yrs||no data||no data|
|Independent Director||1.58yrs||US$83.28k||no data|
Experienced Board: LTIA's board of directors are considered experienced (5.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: LTIA insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 50.2%.
Aptose Biosciences Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Aptose Biosciences Inc.
- Ticker: LTIA
- Exchange: DB
- Founded: 1986
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: CA$641.429m
- Listing Market Cap: CA$411.054m
- Shares outstanding: 76.27m
- Website: https://www.aptose.com
Number of Employees
- Aptose Biosciences Inc.
- 12770 High Bluff Drive
- Suite 120
- San Diego
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|APTO||NasdaqCM (Nasdaq Capital Market)||Yes||Common Shares||US||USD||Jul 2007|
|APS||TSX (The Toronto Stock Exchange)||Yes||Common Shares||CA||CAD||Jul 2007|
|LTIA||DB (Deutsche Boerse AG)||Yes||Common Shares||DE||EUR||Jul 2007|
|0UI8||LSE (London Stock Exchange)||Yes||Common Shares||GB||CAD||Jul 2007|
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in the United States. Its clinical programs is APTO-253, which is a Phase Ib clinical trial for the treatment of patients with relapsed/refractory blood cancers, including acute myeloid leukemia and high-risk myelodysplastic syndrome. It has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a bioavailable non-covalent small molecule that is in Phase I clinical trial for the treatment of patients with relapsed/refractory acute myeloid leukemia and various B-cell malignancies. The company also has an agreement with OHM Oncology for the development, manufacture, and commercialization of APL-581 for the treatment of hematologic malignancies, as well as related molecules. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in San Diego, California.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/03/29 23:23|
|End of Day Share Price||2020/03/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.